Evaluation and research in a common laboratory with Kyoto University.
Our headquarters and research laboratory are located in Kyoto-University Katsura Venture Plaza, where Kyoto University nurtures the creation of new businesses utilizing new ideas/technologies and intellectual properties.
To contribute to the health of people throughout the world through provision of special blood cells produced using regenerative medicine technology.
We produce and provide homogeneous and high precision human blood cells to drastically streamline the evaluation of efficacy and safety of drugs and functional materials, as well as the research of infectious diseases. We also sell evaluation kits and offer various contract evaluation services.
Name of company :
MiCAN Technologies, Inc.
Kyoto-University Katsura Venture Plaza, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan
Kazuo Miyazaki, Chief Executive Officer
Business lineup :
Provision (sales) of blood cell-like cells for research using regenerative medicine technologies
Evaluation service for pharmaceutical development(contract service) using the above-stated blood cell-like cells
Contract service of various tests using the above-stated blood cell-like cells based on alternative methods to animal testing
Accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry
Awarded a grand prize of GLOBIS Venture Challenge
Development of red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University, patent application
Started development of myeloid cells for research of viruses (Mylc cells, second product)
Established a research and development base at Kyoto-University Katsura Venture Plaza
Started release of red blood-like cells (prototype product of Mpv cells)
Patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University
Transferred the Headquarters to Kyoto-University Katsura Venture Plaza
Adopted for the Economic Gardening Support Grant supported by Kyoto Industrial Support Organization 21
Certified as Management of Wisdom by the Kyoto Chamber of Commerce and Industry
Expanded the Headquarters and Laboratory
Signed a collaborative research agreement on the development of culture medium with Nissui Pharmaceutical Co., Ltd.
Started release of myeloid cells for research of viruses (prototype product)
Raised \127,000,000 by allocation of shares to third parties including Osaka University Venture Capital Co., Ltd. (series A)
Started collaborative research on corona virus using Mylc cells with Osaka University
elected in Support for Improvement Research, Technology Development Project for Measures to Control Viral Infections, by AMED
When I was working in India in my previous career, a number of coworkers succumbed to infectious diseases such as malaria and dengue. Vivax malaria, for which rapid development of new drugs is desired. Dengue fever, for which people are waiting for the development of a vaccine. All research and development of drugs for infectious diseases mediated by blood require a huge number of specific blood cells, and the difficulty in procuring them was the largest cause of the delay in the development of drugs and vaccines.
Thus, I made up my mind to produce and provide the specific blood cells required in large quantity at low price using regenerative medicine technology, a cutting-edge technology of Japan.
After I returned to Japan, my business plan was accepted in the Support System for Venture Companies Solving Unmet Medical Needs of the Ministry of Economy, Trade and Industry in 2015. Then, my business went into full-scale operation and I established my company in 2016. After that, I have received various business support from local governments, associations, and investment institutions and won awards from multiple organizations, and I have been energetically developing blood cell-like cells and providing them to the world with like-minded colleagues and employees.
In 2020, the world is in the midst of the COVID-19 pandemic. In this situation, I sincerely hope that MiCAN’s blood cells can help accelerate the development of new drugs and vaccines.